SCHEMBL27199088

SCHEMBL27199088

CCCCCCCCCCCCCCCC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](C(=O)O)C(C)C

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC6A5 Q9Y345 1/20 0.68
▸ FAAH O00519 2/20 0.54
▸ CNR1 P21554 2/20 0.54
▸ CNR2 P34972 2/20 0.54
▸ SLC15A2 Q16348 1/20 0.51
▸ EPHX2 P34913 1/20 0.46
▸ REN P00797 2/20 0.44
▸ PLA2G2A P14555 1/20 0.44
▸ PLA2G5 P39877 1/20 0.44
▸ PSMB5 P28074 2/20 0.43
▸ ITGB2 P05107 1/20 0.43
▸ ICAM1 P05362 1/20 0.43
▸ ITGAL P20701 1/20 0.43
▸ HRH3 Q9Y5N1 3/20 0.42
▸ ACE2 Q9BYF1 1/20 0.42
▸ NOD1 Q9Y239 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27199097 1.00 SLC6A5 (0.68) SLC6A5FAAHCNR1CNR2SLC15A2
SCHEMBL28520371 0.94 SLC6A5 (0.62) SLC6A5FAAHCNR1CNR2SLC15A2
SCHEMBL27199089 0.92 SLC6A5 (0.66) SLC6A5FAAHCNR1CNR2SLC15A2
SCHEMBL27199085 0.89 SLC6A5 (0.60) SLC6A5FAAHCNR1CNR2SLC15A2
SCHEMBL27199086 0.89 SLC6A5 (0.60) SLC6A5FAAHCNR1CNR2SLC15A2
SCHEMBL17244053 0.88 SLC6A5 (0.71) SLC6A5FAAHCNR1CNR2SLC15A2
SCHEMBL4348859 0.87 SLC6A5 (0.87) SLC6A5FAAHCNR1CNR2SLC15A2
SCHEMBL13279669 0.87 SLC6A5 (0.87) SLC6A5FAAHCNR1CNR2SLC15A2
SCHEMBL9664374 0.87 SLC6A5 (0.87) SLC6A5FAAHCNR1CNR2SLC15A2
SCHEMBL15649758 0.87 SLC6A5 (0.87) SLC6A5FAAHCNR1CNR2SLC15A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124520-A1 N-ACYLATED HISTIDINE DIPEPTIDES AS ANTICANCER AGENTS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2024-04-18 — — US claimed
CN-114585635-A N-acylated histidine dipeptides as anti-cancer agents 小利兰·斯坦福大学托管委员会 2022-06-03 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124520-A1 N-ACYLATED HISTIDINE DIPEPTIDES AS ANTICANCER AGENTS NAALAD2, ASNS, AMDHD2 SLC6A5 2993/4885FAAH 1636/4885CNR1 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback